5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-i midazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Details for Australian Patent Application No. 2005277432 (hide)

Owner Quest Pharmaceutical Services L.L.C.

Inventors Yang, Fude

Agent Griffith Hack

Pub. Number AU-B-2005277432

PCT Pub. Number WO2006/023562

Priority 60/602,736 19.08.04 US

Filing date 17 August 2005

Wipo publication date 2 March 2006

Acceptance publication date 24 November 2011

International Classifications

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/4166 (2006.01)

Event Publications

15 March 2007 PCT application entered the National Phase

  PCT publication WO2006/023562 Priority application(s): WO2006/023562

10 May 2007 Change of Name(s) of Applicant(s), Section 104

  Quest Pharmaceutical Services (QPS) The name of the applicant has been changed to Quest Pharmaceutical Services L.L.C.

24 November 2011 Application Accepted

  Published as AU-B-2005277432

22 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005277434-Non-protein foaming compositions and methods of making the same

2005277412-Tinted contact lenses with combined limbal ring and iris patterns